Strategies in Managing Cold Agglutinin Disease

Jeremy Lorber, MD, explains what is known about the pathophysiology of a rare autoimmune hemolytic anemia, cold agglutinin disease.

Mihir Raval, MD, MPH, comments on the difference between cold agglutinin disease and other autoimmune hemolytic anemias.

Health care professionals who treat patients with cold agglutinin disease, a rare autoimmune hemolytic anemia, comment on symptoms that make the condition difficult to diagnose and remark on the burden on patients.

Payers comment on main drivers of health care utilization among patients with cold agglutinin disease.

Diagnostic criteria used by health care professionals who manage patients with autoimmune hemolytic anemias to help distinguish cold agglutinin disease from other medical conditions.

Clinicians offer their perspectives on establishing treatment goals for patients with cold agglutinin disease and describe how they measure treatment response.

Payer considerations regarding the measurement of treatment outcomes for patients with cold agglutinin disease, and resources available to help support patients through their care continuum.

A panel of clinicians and payers highlight challenges that impact the treatment of a rare autoimmune hemolytic anemia, cold agglutinin disease.

An overview of the roles of plasmapheresis, IVIG, transfusions, and corticosteroids as treatment for patients with cold agglutinin disease.

Special considerations educating health care professionals and patients about lifestyle interventions and cold avoidance for cold agglutinin disease.

The rationale for treating patients with cold agglutinin disease with anti–B-cell therapies such as rituximab, bortezomib, or daratumumab based on supporting data.

Criteria that support coverage decisions for anti–B-cell therapies for cold agglutinin disease, which are not currently FDA approved.

Clinicians comment on their approaches when treating patients with cold agglutinin disease with an anti–B-cell therapy.

Payers react to gaps that impact coverage decisions for therapies available off-label for cold agglutinin disease.

During a discussion on the next frontier of medicine for cold agglutinin disease, stakeholders react to the rationale for studying newer, novel complement-targeted therapies.

Payers debate criteria for coverage of novel targeted therapies under investigation as use as novel complement therapy for cold agglutinin disease.

Considerations regarding where newer, novel complement therapies will likely fit into the treatment landscape for patients with cold agglutinin disease.

Take-aways from a discussion on the management of cold agglutinin disease, with expert insight on navigating the healthcare system to optimize patient care.